

Title	Country	Official No.	Case Status	Earliest Priority
Stable Hydroalcoholic Oral Spray Formulations and Methods	Canada	2649895	Registered	19-Apr-07
Mucosal Active Agent Delivery	Australia	2017351744	Pending	31-Oct-16
Mucosal Active Agent Delivery	Brazil	BR112019008565.3	Pending	31-Oct-16
Mucosal Active Agent Delivery	Canada	3041112	Pending	31-Oct-16
Mucosal Active Agent Delivery	China	201780067280.X	Pending	31-Oct-16
Mucosal Active Agent Delivery	European Patent Office	17865329.1	Pending	31-Oct-16
Mucosal Active Agent Delivery	India	201927015960	Pending	31-Oct-16
Mucosal Active Agent Delivery	Japan	2019-523864	Pending	31-Oct-16
Mucosal Active Agent Delivery	Republic of Korea	10-2019-7014312	Pending	31-Oct-16
Mucosal Active Agent Delivery	Mexico	MX/a/2019/004894	Pending	31-Oct-16
Mucosal Active Agent Delivery	USA	16/345098	Pending	31-Oct-16
Use of Anagrelide for Treating Cancer	Australia	2015370666	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Austria	EP3236967	Registered	EP3236967
Use of Anagrelide for Treating Cancer	Belgium	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	China	2015800751658	Pending	22-Dec-14
Use of Anagrelide for Treating Cancer	Denmark	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Europe	EP3236967	Validated	22-Dec-14
Use of Anagrelide for Treating Cancer	Europe	19203051.8	Pending	22-Dec-14
Use of Anagrelide for Treating Cancer	Finland	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	France	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Germany	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Ireland	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Italy	EP3236967	Registered	22-Dec-14

Use of Anagrelide for Treating Cancer	Japan	2017-534600	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Japan	2020- 101165	Pending	22-Dec-14
Use of Anagrelide for Treating Cancer	Netherlands	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Norway	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Poland	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Portugal	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Spain	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Sweden	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Switzerland	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	Turkey	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	United Kingdom	EP3236967	Registered	22-Dec-14
Use of Anagrelide for Treating Cancer	USA	15/538,326	Pending	22-Dec-14
Oral Spray Formulations and Methods for Administration of Sildenafil	Hong Kong	1183818	Registered	7-Jun-10
Oral Spray Formulations and Methods for Administration of Sildenafil	Hong Kong	HK1199843	Registered	5-Dec-11
Oral Spray Formulations and Methods for Administration of Sildenafil	USA	9,186,321	Registered	5-Dec-11